Table 3.

Predictive hazard ratios for treatment effect for TTP in patients treated with docetaxel + gemcitabine vs docetaxel alone. Values shown for multivariate analysis for the whole subset, and for the focused set of analyses performed on the non-luminal subset ^a Basal like + HER2E

	Whole cohort			Non-luminal subseta
Biomarker	HR (95% CI)		Pinteraction	HR (95% CI)		Pinteraction
	Low	High		Low	High
CD8 iTILs count ≤10 vs >10	0.71 (0.49–1.02)	0.73 (0.43–1.22)	0.93	0.42 (0.21–0.81)	0.76 (0.33–1.74)	0.27
CD8 sTILs count ≤30 vs >30	0.80 (0.45–1.40)	0.70 (0.51–0.96)	0.79	0.31 (0.10–1.02)	0.63 (0.35–1.13)	0.29
FOXP3 iTILs count <2 vs ≥2	0.59 (0.39–0.89)	0.88 (0.56–1.38)	0.21	0.22 (0.09–0.52)	0.92 (0.47–1.80)	0.01
FOXP3 sTILs count <3 vs ≥3	0.76 (0.41–1.40)	0.72 (0.51–1.02)	0.87
LAG3 iTILs count 0 vs ≥1	0.69 (0.50–0.96)	0.77 (0.37–1.63)	0.79
LAG3 sTILs count 0 vs ≥1	0.71 (0.48–1.04)	0.69 (0.42–1.13)	0.96
PD-1 iTILs count 0 vs ≥1	0.68 (0.48–0.96)	0.88 (0.47–1.67)	0.48
PD-1 sTILs count 0 vs ≥1	0.75 (0.49–1.14)	0.66 (0.42–1.02)	0.66
PD-L1 < 1% vs ≥1%	0.68 (0.48–0.95)	0.85 (0.39–1.88)	0.60
HE TILs ≤1% vs >1%	0.66 (0.45–0.98)	0.90 (0.54–1.48)	0.35
CD163 TAM <56 vs ≥56	0.72 (0.47–1.10)	0.51 (0.32–0.83)	0.30	0.39 (0.16–0.93)	0.64 (0.32–1.30)	0.38

Abbreviations: HR: hazard ratio, TTP: time to progression, iTILs: intratumoral tumor infiltrating lymphocytes, sTILs: stromal tumor infiltrating lymphocytes, HE: hematoxylin-eosin, TAM: tumor associated macrophages.